Burning Rock Biotech (BNR) Cost of Revenue (2019 - 2026)

Burning Rock Biotech (BNR) has reported Cost of Revenue for 8 consecutive years, with $4.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cost of Revenue fell 11.77% year-over-year to $4.3 million; the TTM figure through Mar 2026 stood at $18.6 million (down 10.32% YoY), while the FY2025 annual figure was $23.6 million, down 9.69% from the prior year.
• Cost of Revenue came in at $4.3 million for Q1 2026 at Burning Rock Biotech, up from $4.0 million in the prior quarter.
• The five-year high for Cost of Revenue was $7.6 million in Q1 2022, with the low at $4.0 million in Q4 2025.
• Average Cost of Revenue over 5 years is $5.7 million, with a median of $5.6 million recorded in 2025.
• Across the five-year window, Cost of Revenue surged 66.95% in 2022 and decreased 20.86% in 2025, its largest moves.
• Year by year, Cost of Revenue stood at $5.9 million in 2022, then rose by 1.89% to $6.1 million in 2023, then dropped by 17.15% to $5.0 million in 2024, then declined by 20.86% to $4.0 million in 2025, then climbed by 9.35% to $4.3 million in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $4.3 million, $4.0 million, and $4.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.